Potentially fatal new trend in performance enhancement: a cautionary note on nitrite
© Petróczi and Naughton; licensee BioMed Central Ltd. 2010
Received: 23 March 2010
Accepted: 29 June 2010
Published: 29 June 2010
Considerable interest has been shown by athletes and scientists in the potential for nitric oxide and associated vasodilators to enhance performance. This study aims to explore potential misuse of vasodilators by the athletes, and to highlight the growing concern over these agents.
Retrospective analyses of anonymous inquiries recorded in the Drug Information Database™ (DID™) between January 2006 and June 2008 (inclusive). In this 30-month period, the DID™ recorded 198,023 inquiries, of which 118,724 were UK Licensed Pharmaceutical products with a further 79,299 inquiries made for substance not found in the database.
Phosphodiesterase type 5 (PDE-5) inhibitors, dominated by Viagra®, ranked 16th among the substance groups. The proportion of the inquiries made regarding PDE-5 inhibitors, especially in comparison to antibiotics, painkillers or alcohol, appears to be above the level that would normally be expected from medical need. No significant change in the months leading up to the Beijing Olympics was observed. On the contrary, the Nitric/Nitrate group showed a notable increase between 2006-2007 and 2008, suggesting a potential increase in interest in using nitric oxide among athletes.
With patents recently filed for the use of agents containing sodium nitrite/nitrate to enhance blood flow for performance enhancement in sport, coupled with anecdotal evidence from internet athlete forums and media, there is a concern that athletes may endanger their health by using vasodilators to enhance athletic performance. PDE-5 inhibitors or chemicals in the nitrate/nitrate group are currently not prohibited or tested for by the doping control agencies but some are highly dangerous to health and can lead to cardiovascular collapse, coma and death. Its promotion among athletes as a performance enhancing supplement is ethically and medically questionable.
The discovery of the vasodilator role of nitric oxide (NO·) has led to a revolution in pharmacology over the past two decades which has brought considerable innovations in NO·-related therapy. Apart from helping to elucidate the mode of action of well established treatments such as nitroglycerine, the contribution of advances in NO· research have mainly exerted an effect in the clinic through advances in the understanding and application of nitrite, a precursor to NO·. Just over a decade ago, the efficiency of NO· production by the metallo-enzyme xanthine oxidoreductase was demonstrated . In vitro and under hypoxia, this enzyme is considerably more effective than nitric oxide synthase at generating NO· . More recently, this phenomenon was observed for deoxyhaemoglobin , leading to the recent demonstration that nitrite has considerable protective effects in a range of cardiovascular conditions, including myocardial infarctions . Nitrite, currently licensed for the treatment of cyanide toxicity, will undoubtedly continue to make a major clinical impact unless a serious side effect emerges. The long term benefits and risks of nitrite therapy have yet to be elucidated although Martindale: The Extra Pharmacopoeia lists the serious side effects as convulsions, cardiovascular collapse, coma and death.
Participants in professional sports can exhibit adept abilities to take advantage of advances in medicine relating to performance enhancement. It is not surprising that many athletes have looked at vasodilators to embellish their performances on the playing field. Reports of reliance on vasodilator drugs used for sexual dysfunction are common, even at the national team level. One report identifies the distributions of Viagra® to a national soccer team playing at high altitude, supposedly without the players' knowledge . This use has also been recognised by sport governing bodies as the World Anti Doping Agency (WADA) currently sponsor a study of the performance enhancing effects of sildenafil (Viagra®) at mild altitude .
One approach to gauging the interests of athletes in vasodilators is to analyse inquiries lodged with the Drug Information Database™ (DID™). The DID™ was developed and hosted by elite sport© and launched in the UK via UK Sport in 2002 and provided a self-check tool for athletes and support personnel (coaches, doctors, pharmacists, teachers, parents) until 2009. The anonymous inquiries were recorded since January 2006, cataloguing some 9,000 inquiries each month, predominantly from athletes themselves. The database contained UK licensed pharmaceutical products and was searchable by trade names and active ingredients, and linked to the current List of Prohibited substances published by the WADA . Information returned on the individual inquiries included in- and out-of competition status of the drug, including differentiation by the route of administration.
The inquiries recorded via the DID™ have been scrutinized and shown to be a reflection of athletes' practices . Beyond and above the evidence reported by Petroczi & Naughton , the validity of the database was further checked by mapping the trend in inquiries made about antihistamines and the onset of common pollen allergies (trees, grass and weeds). The close match between the inquiries and the seasonal variations in pollen allergies (data not shown) provided further reassurance for the validity.
The UK Sport's Drug Information Database (DID™) has been previously interrogated to gain an insight into what substances athletes and their support personnel are interested in . In order to elucidate the potential use or misuse of vasodilators, data previously downloaded from the DID™ were re-analysed. The data, limited to inquiries made in the UK, were downloaded in July 2008 in two segments:
Dataset 1: Time covering between January 1, 2006, and December 31, 2007.
Dataset 2: Six sets of 2008, in monthly segments, to monitor any changes during the months leading up to the 2008 Beijing Olympic Games. Comparing to previous analysis including all inquiries  and based on 2006-2007 (24 month period) statistics, enquires made in the UK formed the majority of the records (75% of "found" and 68.5% of "not found").
Keywords used for analysing the DID™ data
Acetildenafil, Lodenafil (Helleva®), Microdenafil, Sildenafil citrate (Viagra®, Revatio®), Tadalafil (Cialis®, Adcirca®), Thiomethisosildenafil, Udenafil (Zydena®) Vardenafil (Levitra®, Vivanza®)
Nitric oxide, Nitrate, Nitrix, NO2®, NO-Xplode®
In order to create meaningful groups of substances for further analysis, the recorded inquiries were ranked in decreasing order and individual contributions to the complete dataset were calculated and expressed as percentages. Previous analysis has shown that the number of inquiries recorded for each substance decreases exponentially with records greater than 200 yielding meaningful information . A total of 45 substances received the highest number of enquires (> 300 for each substance), which individually account for at least 0.25% of the entire database. These popular substances were the focus of the analyses conducted for this report. Less popular formulations of these substances in the remainder of the database were also included. Queries about substances that match the database contents are listed as "found" whereas those that have no match are labelled as "not found". The latter category include those queries that were mistyped or do not correspond to a substance in the database. Thus, the "not found" category can provide information on emerging substances/names.
Results and Discussion
The combined data (January 2006 to June 2008) contain 118,724 inquiries in the "found" dataset with the highest one being Lemsip preparations with 3,006 records (2.53%), followed by caffeine (2,045, 1.72%), ibuprofen (1709, 1.44%), paracetamol (1,648, 1.39%), ephedrine (1,440, 1.21%), and salbutamol containing preparations (1,235, 1.04%). Viagra® was among the top 50 inquiries with 338 inquiries (0.28%). When combining all PDE-5 inhibitors, before grouping, there were 484 (0.41%) inquiries (equating to 25th place) within this 30-month period.
Evidence from queries made to the DID™ along with sports internet discussion boards identifies a growing interest in blood enhancing agents including Viagra® and nitric oxide based agents. A particular concern is the promotion of these drugs among athletes as performance enhancing supplements. Many athletes will be unaware of the potency and side effects associated with their abuse. In particular, sodium nitrite, the nitric oxide precursor, has led to fatalities. In a recent event, sodium nitrite was mistakenly used as salt for food preparation and led to two reported coma cases and four deaths , which highlights the toxicity at small doses that can occur outside of clinical supervision.
Many of the supplement products do not contain sodium nitrite, and it is not suggested here that the products on the market are themselves dangerous. However, agents to enhance blood flow for performance enhancement in sport have been subject to patent protection and in one case, the composition contains the active agents as sodium nitrite/nitrate . The possibility that use of the other supplement products may lead to the use of dangerous products is the primary concern. Clearly, the clinical applications of nitrite are immense despite the potential drawbacks of, yet to be fully explored, therapeutic windows . Recent reports of nitrite induced cardiovascular protection, based on proteome changes , have yet to be ascribed a mechanism. However, it is clear that oxidative damage occurs, as shown by the authors, which may elicit the protective effects leading to questions regarding long term use . In recent years, there has been spreading speculation regarding the potential misuse of vasodilators by the athletic population . PDE-5 inhibitors are currently not prohibited by the WADA but the agency has funded research to investigate the performance-enhancing potential of sildenafil .
Nitrite/Nitrate and related products are not on the WADA prohibited list of chemicals either; and as an endogenous species and component of foodstuffs a regulatory test is unlikely. From our current knowledge of doping reports, athletes are willing to use non-prohibited and OTC medications to boost their athletic performance [10–12]. It is concerning that these products frequently fall outside of medical supervision. Thus, a more acceptable policy is warranted, along with public awareness initiatives.
This report demonstrates that, in contrast to interest in prescription vasodilators, athletes exhibited an increasing interest in "nitric-oxide precursor" vasodilators as observed in the DID™ records. There was a marked increase in inquiries made about these supplements leading up to the Beijing Olympics. Without medical supervision, use of vasodilators, especially (sodium) nitrite is potentially very serious and the adverse effects should be publicised.
The authors thank UK Sport, especially Joe Marshall, Jerry Bingham and Allison Holloway, for facilitating access to the DID™ database. The study was partially supported by the South West London Academic Alliance.
- Zhang Z, Naughton D, Winyard PG, Benjamin N, Blake DR, Symons MCR: Generation of nitric oxide by a nitrite reductase activity of xanthine oxidase: A potential pathway for nitric oxide formation in the absence of nitric oxide synthase activity. Biochem Biophys Res Commun. 1998, 249: 767-72. 10.1006/bbrc.1998.9226.View ArticlePubMedGoogle Scholar
- Cosby K, Partovi KS, Crawford JH, Patel RP, Reiter CD, Martyr S, Yang BK, Waclawiw MA, Zalos G, Xu X, Huang KT, Shields H, Kim-Shapiro DB, Schechter AN, Cannon RO, Gladwin MT: Nitrite reduction to nitric oxide by deoxyhemoglobin vasodilates the human circulation. Nature Med. 2003, 9: 1498-505. 10.1038/nm954.View ArticlePubMedGoogle Scholar
- Huang Z, Shiva S, Kim-Shapiro DB, Patel RP, Ringwood LA, Irby CE, Huang KT, Ho C, Hogg N, Schechter AN, Gladwin MT: Enzymatic function of hemoglobin as a nitrite reductase that produces NO under allosteric control. J Clin Invest. 2005, 115: 2099-107. 10.1172/JCI24650.PubMed CentralView ArticlePubMedGoogle Scholar
- Viagra® treatment for footballers. BBC News. accessed 17 April 2009, [http://news.bbc.co.uk/1/hi/world/americas/8005391.stm]
- Rundell KW, Dempsey W, Uhranowsky K: Decreased pulmonary artery pressure by oral sildenafil ingestion at mild altitude and during exercise in air pollution increases exercise performance. WADA funded grant proposal. 2007, [http://www.wada-ama.org/rtecontent/document/Rundell_07E04KR.pdf]Google Scholar
- Petroczi A, Naughton DP, Mazanov J, Holloway A, Bingham J: Performance enhancement with supplements: incongruence between rationale and practice. J Intl Soc Sports Nutr. 2007, 4: 19-10.1186/1550-2783-4-19.View ArticleGoogle Scholar
- Petroczi A, Naughton DP, Mazanov J, Holloway A, Bingham J: Limited agreement exists between rationale and practice in athletes' supplement use for maintenance of health: a retrospective study. Nutr J. 2007, 6: 34-10.1186/1475-2891-6-34.PubMed CentralView ArticlePubMedGoogle Scholar
- Petroczi A, Naughton DP, Pearce G, Bloodworth A, Bailey R, McNamee M: Nutritional supplement use by elite young UK athletes: fallacies of advice regarding efficacy. J Intl Soc Sports Nutr. 2008, 5: 22-10.1186/1550-2783-5-22.View ArticleGoogle Scholar
- Petroczi A, Naughton DP: The age-gender-status profile of high performing athletes in the UK taking nutritional supplements: lessons for the future. J Intl Soc Sports Nutr. 2008, 5: 2-10.1186/1550-2783-5-2.View ArticleGoogle Scholar
- Corrigan B, Kazlauskas R: Medication use in athletes selected for doping control at the Sydney Olympics (2000). Clin J Sport Med. 2003, 13: 33-40. 10.1097/00042752-200301000-00007.View ArticlePubMedGoogle Scholar
- Tsitsimpikou C, Tsiokanos A, Tsarouhas K, Schamasch P, Fitch K, Valasiadis D, Jamurtas A: Medication use by athletes at the Athens 2004 Summer Olympic Games. Clin J Sport Med. 2009, 19: 33-8. 10.1097/JSM.0b013e31818f169e.View ArticlePubMedGoogle Scholar
- Suzic Lazic J, Dikic N, Radivojevic N, Mitrovic N, Lazic M, Zivanic S, Suzic S: Dietary supplements and medications in elite sport - polypharmacy or real need?. Scand J Med Sci Sports. 2009, DOI 10.1111/j.1600-0838.2009.01026.xGoogle Scholar
- Strano Rossi S, Gabriella Abate M, Cristina Braganò M, Botrè F: Consumo de sustancias estimulantes y drogas de abuso en el deporte: la experiencia italiana [Use of stimulants and drugs of abuse in sport: the Italian experience]. Adicciones. 2009, 21: 239-42.PubMedGoogle Scholar
- Taioli E: Use of permitted drugs in Italian professional soccer players. Br J Sports Med. 2007, 41: 439-41. 10.1136/bjsm.2006.034405.PubMed CentralView ArticlePubMedGoogle Scholar
- Alaranta A, Alaranta H, Helenius I: Use of prescription drugs in athletes. Sports Med. 2008, 38: 449-63. 10.2165/00007256-200838060-00002.View ArticlePubMedGoogle Scholar
- Mazanov J, Petroczi A, Holloway A, Bingham J: Towards an empirical model of performance enhancing supplement use: A pilot study among high performance UK athletes. J Sci Med Sport. 2008, 11: 185-90. 10.1016/j.jsams.2007.01.003.View ArticlePubMedGoogle Scholar
- Papadopoulos FC, Skalkidis I, Parkkari J, Petridou E, "Sports Injuries" European Union Group: Doping use among tertiary education students in six development countries. Eur J Epidemiol. 2006, 21: 307-13. 10.1007/s10654-006-0018-6.View ArticlePubMedGoogle Scholar
- Petroczi A, Aidman EV: Psychological drivers in doping: the life-cycle model of performance enhancement. Subst Abuse Treat Prev Policy. 2008, 3: 7-10.1186/1747-597X-3-7.PubMed CentralView ArticlePubMedGoogle Scholar
- The Prohibited List is updated annually following an extensive consultation process facilitated by WADA. World Anti Doping Agency. [http://www.wada-ama.org/en/World-Anti-Doping-Program/Sports-and-Anti-Doping-Organizations/International-Standards/Prohibited-List]
- Petróczi A, Naughton DP: Popular drugs in sport: descriptive analysis of the inquiries made via the Drug Information Database (DID). Br J Sports Med. 2009, 43: 811-7. 10.1136/bjsm.2008.052894.View ArticlePubMedGoogle Scholar
- Lundberg J, Weitzberg E: Performance enhancing composition and use thereof. European Patent No. 08712839, [http://www.wipo.int/pctdb/en/wo.jsp?WO=2008105730]Google Scholar
- Braun M, Wassmer G, Klotz T, Reifenrath B, Mathers M, Engelmann U: Epidemiology of erectile dysfunction: results of the 'Cologne Male Survey'. Int J Impot Res. 2000, 12: 305-11. 10.1038/sj.ijir.3900622.View ArticlePubMedGoogle Scholar
- Food poisoning kills 4 kids in SW China. China Daily. 2009, [http://www.chinadaily.com.cn/china/2009-05/19/content_7792857.htm]
- Perlman DH, Bauer SM, Ashrafian K, Bryan NB, Garcia-Saura MF, Lim CC, Fernandez BO, Infusini G, McComb ME, Costello CE, Feelisch M: Mechanistic insights into nitrite-induced cardioprotection using an integrated metabolomic/proteomic approach. Circ Res. 2009, 104: 796-804. 10.1161/CIRCRESAHA.108.187005.View ArticlePubMedGoogle Scholar
- Mason C: Gold medals, vitamin V and miscreant sports. Can Med Assoc J. 2008, 179 (3): 219-21. 10.1503/cmaj.080993.View ArticleGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.